Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
08 8월 2023 - 8:00PM
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”)
(NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company,
announced today the appointment of Dr. Arash Yavari as the Chair of
its Development Advisory Committee (“DAC”), a team comprised of
industry veterans in immuno-oncology drug development and
regulatory strategy.
“We are pleased to welcome Dr. Arash Yavari as
the Chair of our Development Advisory Committee,” said Dr. Fahar
Merchant, President and CEO of Medicenna. “We have been working
closely with Dr. Yavari on MDNA11 for the past two years and have
appreciated his considerable expertise in drug development. Dr.
Yavari’s contributions will be instrumental in advancing our
planned Phase 2 dose expansion and combination studies which are
expected to commence in the third and fourth calendar quarters of
this year, respectively.”
Dr. Yavari stated: “I look forward to assisting
Medicenna’s team in their efforts to provide well-tolerated and
more effective, cytokine-based, precision immunotherapies such as
MDNA11 to patients with difficult-to-treat cancers. The encouraging
data generated to date with MDNA11 in the ongoing ABILITY study
highlights the promise of Medicenna’s innovative IL-2 superkines,
bizaxofusp for recurrent glioblastoma and, more broadly, the
BiSKITs platform. These novel approaches and their expected synergy
with a range of other cancer treatment modalities have the
potential to provide long-lasting clinical benefit to patients with
advanced cancer.”
Dr. Arash Yavari is a physician-scientist with
over 20 years of broad clinical, scientific and industry drug
development experience. He has extensive expertise in early
clinical development and scientific strategy across a range of
therapeutic areas, including immuno-oncology, hemato-oncology,
inflammation, autoimmunity, cardiometabolic and rare disease. Dr
Yavari is a University Research Lecturer and Principal Investigator
at the Radcliffe Department of Medicine, University of Oxford, CSO
of Imbria Pharmaceuticals, and serves as Senior Drug Development
Clinician with Weatherden, a London-based biotech-focused
consulting organization. Dr. Yavari holds a BSc and MBBS from the
University of London, and a DPhil from the University of
Oxford.
About MedicennaMedicenna is a
clinical stage immunotherapy company focused on the development of
novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines
and first in class Empowered Superkines. Medicenna’s long-acting
IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior
CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor
alpha) affinity thereby preferentially stimulating cancer killing
effector T cells and NK cells. Medicenna’s IL-4 Empowered
Superkine, bizaxofusp (formerly MDNA55), has been studied in 5
clinical trials including a Phase 2b trial for recurrent GBM, the
most common and uniformly fatal form of brain cancer. Bizaxofusp
has obtained FastTrack and Orphan Drug status from the FDA and
FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ program,
(Bifunctional SuperKine ImmunoTherapies) is designed to enhance the
ability of Superkines to treat immunologically “cold” tumors.
Forward Looking StatementsThis
news release contains forward-looking statements within the meaning
of applicable securities laws that relate to the future operations
of the Company, plans and projections and other statements,
including statements on the development potential and milestones of
MDNA11. Forward-looking statements are often identified by terms
such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”,
“seek”, “potentially” and similar expressions. and are subject to
risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such
statements. Important factors that could cause actual results to
differ materially from the Company’s expectations include the risks
detailed in the latest Annual Information Form and Annual Report on
Form 20-F of the Company and in other filings made by the Company
with the applicable securities regulators from time to time
in Canada and the United States.
The reader is cautioned that assumptions used in
the preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management, may prove to be incorrect and actual results may differ
materially from those anticipated. Forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement. The forward-looking statements contained in
this news release are made as of the date hereof and except as
required by law, we do not intend and do not assume any obligation
to update or revise publicly any of the included forward-looking
statements.
Further Information
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer,
ewilliams@medicenna.com
Delphine Davan, Vice President, Investor Relations and Corporate
Communications, ddavan@medicenna.com
Media Contact
For media inquiries, please contact:
Tony Russo, Russo Partners,
212-845-4251, tony.russo@russopartnersllc.com
Medicenna Therapeutics (TSX:MDNA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Medicenna Therapeutics (TSX:MDNA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024